# Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome

> **NCT06053983** · PHASE4 · COMPLETED · sponsor: **Rawalpindi Medical College** · enrollment: 126 (actual)

## Conditions studied

- Mi Q Wave

## Interventions

- **DEVICE:** Turbox CRP kit
- **DRUG:** rosuvastatin 20 mg,
- **DRUG:** atorvastatin 40 mg

## Key facts

- **NCT ID:** NCT06053983
- **Lead sponsor:** Rawalpindi Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-01
- **Primary completion:** 2023-08-01
- **Final completion:** 2023-08-01
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06053983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06053983, "Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT06053983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*